NSI-189 Phase 2 update


"40 mg dose showed statistically significant improvement on Cogscreen objective cognitive measures of attention and memory

Two additional self-rated secondary endpoints (CPFQ and QIDS) showed statistically significant improvements in depressive symptoms with procognitive benefits, reinforcing the benefit with SDQ endpoint reported previously

NSI-189 appeared to be safe and well tolerated with no serious adverse events"

NSI-189 is “in clinical development for MDD and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke.”

More info:


Probably a load of crap

Why is that?


1 Like

Going good… we need it…!!! I have serious cognitive impairment…!!! Hope it passes phase 3 as well… Sup @twinklestars… ?? What are u doing…??

Did not reach any significant end points … what the hell…!!!

They’re testing it in major depressive disorder, and it didn’t improve patient scores on the scale they use for that, MADRS. But it did show a statistically significant benefit on Cogscreen measures of attention and memory.

It’s procognitive.

1 Like